AC Immune reports 1H results (ACIU:NASDAQ)
· seekingalpha.com
AC Immune (ACIU) reports 1H 2026 revenue surged to CHF16.2M on Lilly & Takeda milestones; cash at CHF75.4M funds into Q4 2027.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...